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Abstract
Background: Multimodal therapy for acromegaly affords adequate disease control for many patients;
however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of
treatment-resistant pituitary tumor growth remains relatively under-explored.
Methods: We assessed the literature for relevant data regarding the surgical, medical and radiother-
apeutic treatment of acromegaly in order to identify the factors that were predictive of aggressive or
treatment-resistant pituitary tumor behavior in acromegaly and undertook an assessment of the rates
of failure to control tumor progression with available treatment modalities.
Results: Young age at diagnosis, large tumor size, high growth hormone secretion and certain histo-
logical markers are predictors of future aggressive tumor behavior in acromegaly. Significant tumor
regrowth occurs in less than 10% of cases thought to be cured surgically, whereas failure to control
tumor growth is seen in less than 1% of patients receiving radiotherapy. Somatostatin analogs induce
a variable degree of tumor shrinkage in acromegaly but up to 2.2% of somatostatin analog-treated
tumors continue to grow. Relative to other therapies, limited data are available for pegvisomant,
but these indicate that persistent tumor growth occurs in 1.6–2.9% of cases followed up regularly
with serial magnetic resonance imaging scans.
Conclusions: Treatment-resistant tumor progression occurs in a small minority of patients with
acromegaly, regardless of treatment modality. Young patients with large tumors or those with high
pre-treatment levels of growth hormone particularly warrant close monitoring for continued
tumor progression during treatment for acromegaly.
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Introduction
Five separate treatment modalities are currently avail-
able for acromegaly: surgery, somatostatin analogs, a
growth hormone (GH) receptor antagonist, dopamine
agonists and radiotherapy. The preferred primary treat-
ment is surgery, as complete resection of an adenoma
can cure the disease in more than three-quarters of
microadenomas, although this decreases to less than
half of macroadenomas (1). Some elderly or debilitated
patients may not be suitable for surgery and others may
decline this option. In cases where surgery fails to con-
trol the condition or is not performed, medical therapy
or radiotherapy is necessary, either alone or in combi-
nation. Disease control in acromegaly is probably
achievable for most patients using multi-modal therapy,
although formal studies in this regard are required. The
characteristics of the minority of patients with treat-
ment-resistant acromegaly and the factors that deter-
mine tumor behavior in these cases have received
relatively little attention. Scant data exist concerning
the natural history of pituitary tumor growth in
acromegaly, as surgery and radiotherapy for acro-
megaly have been available for nearly 100 years and
medical therapy has existed for about 30 years. With-
out such data it is difficult to predict exactly which
tumors are likely to recur during medium- to long-
term follow-up. In order to examine this issue more
clearly we undertook an assessment of the literature
to identify patient characteristics and structural,
molecular and genetic factors that may pre-dispose to
aggressive pituitary tumor behavior in acromegaly.
Using this information, we assessed relevant reports
of continued pituitary adenoma growth in acromegaly
with surgery, medical therapy and radiotherapy.
Factors associated with aggressive
pituitary tumor activity
Patient characteristics.
Age In a detailed magnetic resonance imaging (MRI)
study of patients with acromegaly, Lundin et al. (2)
reported that pituitary tumor volume was inversely
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related to age. Similarly, two single-center studies have
reported an inverse relationship between the age of
patients and the likelihood of tumor persistence follow-
ing surgery. In a French series of 48 patients with acro-
megaly, those with persistent disease after surgery were
younger than satisfactorily treated patients (3). Abosch
et al. (4) also found younger age to be a predictor of dis-
ease persistence after surgery. This finding may be par-
tially a function of lower hormonal activity in older
acromegalic patients. van der Lely et al. (5) reported
that older patients with acromegaly have lower circu-
lating GH and insulin-like growth factor-I (IGF-I)
levels, and GH suppression with octreotide therapy is
more marked in elderly patients compared with
younger individuals. Related evidence exists in patients
with residual nonfunctioning pituitary adenomas post
surgery, as younger patients had more rapidly growing
tumor remnants and a shorter time to tumor-volume
doubling (6).
Tumor characteristics
Tumor size and GH secretion In many surgical series,
patients with acromegaly who harbor extensive macro-
adenomas or those who exhibit high preoperative cir-
culating concentrations of GH are more likely to have
persistent disease despite transsphenoidal resection
(4, 7–11). Larger tumors in acromegaly have also
been associated with more frequent invasiveness,
younger age at diagnosis and poorer responses to
therapy (12). These results are in keeping with other
evidence outlined above demonstrating an inverse
relationship between age and tumor volume (2).
Tumor morphology Extensive morphological studies
have been performed in acromegaly using surgically
resected pituitary adenoma tissue. Differences in tumor
behavior have been noted based on histological staining,
with hormonal secretion from tumors exhibiting sparse
granular staining being less responsive to pharmacologi-
cal suppression than densely granulated adenomas (13).
Overall, sparsely granulated adenomas aremore likely to
be invasive or to exhibit suprasellar extension, and sur-
gery is less likely to be successful in these cases. Poorer
outcomes, such as earlier age at diagnosis, larger
tumor size and more frequent extrasellar extension
have been associated with GH-secreting adenomas
which exhibit dot-like cytokeratin staining, compared
with those with a perinuclear/fibrillary cytokeratin
staining pattern (12). Re-operations and incomplete
tumor resection were four times more frequent in
patients with a dot-like cytokeratin pattern than in
those with the peri-fibrillary pattern, whereas the
mean interval to re-operation was 16 months in the
former group compared with 57 months in the latter
group (14). Immunohistochemical staining of resected
pituitary tumor tissue for anti-Ki-67 monoclonal
antibody (MIB-1) has been shown to correlate with
dural and cavernous sinus invasiveness (15, 16), includ-
ing in patients with acromegaly (17).
At this time, matrix metalloproteinases, indices of
angiogenesis and markers of cell-cycle regulation
(cyclins) do not appear to play a distinctive role in indi-
cating aggressive/treatment-resistant tumor behavior
in acromegaly as compared with other pituitary
tumor types (18–20).
Genetic markers
A variety of genetic mutations and signalling abnorm-
alities have been identified from studies of GH-secreting
pituitary adenoma tissues, although inherited disorders
account for only a minority of pituitary adenomas (21).
An activating mutation of the Gsa gene (gsp) is present
in approximately one-quarter of cases of acromegaly
and tumors from such patients may be less aggressive
than those not harboring the mutation (22). Despite
extensive study of other molecular and genetic markers
(e.g. Growth arrest and DNA-damage-inducible protein
(GADD) 45 and pituitary tumor transforming gene
(PTTG)) and tumor behavior in pituitary adenomas, a
strong correlation between any of these markers and
tumor aggression in acromegaly has yet to be demon-
strated (23–26). Patients with multiple endocrine neo-
plasia-1 (MEN-1) exhibit more aggressive pituitary
disease in general than patients with sporadic tumors
(27). Perhaps reflecting this finding, a large study of
324 patients with MEN-1 reported that all 12 patients
with acromegaly had macroadenomas (28). Familial
acromegaly occurs very rarely in the absence of
MEN-1, but is associated with early onset of disease,
and larger/extensive tumors have been reported (29)
compared with sporadic acromegaly, although not
invariably (30).
Tumor growth and persistence rates
following treatment for acromegaly
Surgery
Transsphenoidal surgery is the treatment of choice in
acromegaly, particularly for patients with microadeno-
mas (,10mm diameter) or uncomplicated macroade-
nomas (1). The surgical cure rate for microadenomas
is around 80% but for macroadenomas it is under
50% using strict biochemical criteria (1); success
rates are more favorable when surgery is performed
by an experienced pituitary surgeon (8). After surgery,
acromegaly frequently persists or recurs in patients
with tumors complicated by extrasellar extension or
invasion of peri-sellar structures. In the largest series
published to date, which included 506 patients with
acromegaly who underwent primary transsphenoidal
surgery, the overall remission rate was 72% in non-
invasive adenomas and 21.6% in invasive tumors (7).
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The recurrence rate following apparent initial surgical
remission can be up to 10% in some series (4, 9, 10).
The most important predictors of unsuccessful outcome
following surgery are large tumor size, extrasellar
extension/invasion (high grade) and high pretreatment
circulating GH levels (11).
Medical therapy
Somatostatin analogs Long-acting somatostatin ana-
logs have been available since the mid-1980s, and depot
formulations are the most frequently chosen form of
medical therapy for acromegaly. Somatostatin analogs
are used as adjunctive therapy for patients with persist-
ent disease post-operatively or in the pre-operative set-
ting to improve physical condition and induce tumor
shrinkage (31). In patients who are unable or unwilling
to undergo transsphenoidal surgery, somatostatin ana-
logs have been employed as primary therapy (32, 33).
Long-acting somatostatin analogs are effective in redu-
cing GH, although results vary depending on baseline
GH levels, the presence of functioning receptors for
somatostatin, and duration of treatment (34, 35). Two
substantial systematic reviews have been performed
recently to examine the effects of primary and adjunctive
somatostatin analog therapy on hormonal control and
tumor shrinkage in acromegaly. In the first study, Freda
(36) estimated that the adjunctive use of lanreotide SR
or octreotide LAR normalized serum IGF-I in 48 and
66% of cases, respectively. GH control was defined as a
random or mean GH level of , 2.0 or ,2.5mg/l,
respectively, or a GH level of,1.0mg/l post oral glucose
load. Adjunctive lanreotide SR or octreotide LAR treat-
ment in acromegaly controlled GH in 49 and 56% of
cases, respectively (36). Primary somatostatin analog
therapy normalized IGF-I in 60% of cases and controlled
GH in 50% of cases overall. One potential confounding
issue that was raised in the review was that octreotide
studies specifically excluded ‘non-responders’, defined
as those patients who exhibited a poor GH suppression
response to a test dose of octreotide at preliminary
screening. Freda (36) reported that octreotide-induced
tumor shrinkage was quite variable with,20% shrink-
age in tumor volume occurring in 8% of patients, 20–
50% shrinkage in 35% of patients and larger degrees of
tumor shrinkage were uncommon (36). Considering
only patients receiving primary somatostatin analog
therapy, results were similar, with 48% overall having
tumor regression, of whom 9% had ,20% shrinkage,
32%had 20–50% shrinkage and 7%had.50% shrink-
age. Bevan (37) recently reported an extensive review of
the effects of short- and long-acting somatostatin ana-
logs on tumor shrinkage. He noted that definitions of
tumor shrinkage, washout times between therapies,
dosages and radiological follow-up were not standar-
dized across most studies in the literature. In a pooled
analysis of 22 studies (n ¼ 478) of subcutaneous octreo-
tide, 45% of patients had tumor shrinkage; this rose to
51% in those receiving primary somatostatin analog
therapy, but was as low as 27% in those on adjunctive
therapy. For octreotide LAR (n ¼ 180), the overall
tumor shrinkage response rate was 57%. In patients
receiving primary medical therapy the response rate
was 80%, and for those receiving adjunctive octreotide
LAR this fell to 28%.When all data from all formulations
of somatostatin analogs were pooled (n ¼ 921), tumor
shrinkage occurred in 42% of cases overall and in 52
and 21% of cases treated with primary or adjunctive
somatostatin analog therapy, respectively (37). The
rates of tumor progression on somatostatin analog
therapy were also assessed in these two systematic ana-
lyses, with Freda (36) reporting that tumor progression
occurred in ,1% of cases. In contrast, Bevan (37) esti-
mated that, of 921 cases included in the analysis, 20 –
or 2.2% – had tumor growth on somatostatin analogs
(37). Failure to control pituitary adenoma growth
occurred in approximately 10% in individual studies
using lanreotide (38, 39) and octreotide (40), which
were not included in that analysis. Another issue that
may confound accurate analysis of tumor behavior in
general is the fluctuation in tumor size to the order of
10–20%, which can be seen during intensive MRI
follow-up in individual acromegalic patients treated
with somatostatin analogs (33). The effects of somato-
statin analogs on tumor size do not appear to be perma-
nent and many groups have reported that, on
withdrawal of octreotide, pituitary adenomas may re-
expand to their original size (41–44). The issue of time
to re-expansion has not been studied systematically in
patients being withdrawn from depot long-acting
somatostatin analog therapy and it is unknownwhether
tumor re-expansion follows a similar 3–4-month time
course to that of increased GH/IGF-I secretion (45). It
appears that somatostatin analogs induce tumor shrink-
age by decreasing adenoma cell size/activity rather than
inducing apoptosis (46, 47).
GH receptor antagonist The GH receptor antagonist,
pegvisomant, is the most recently developed treatment
for acromegaly. Pegvisomant blocks the activation of
the GH receptor by GH, leading to a reduction in IGF-
I secretion. In patients with acromegaly who were trea-
ted with pegvisomant for up to 18 months, circulating
IGF-I levels were normalized in 97% of cases (48).
Tumor shrinkage is not a feature of pegvisomant
therapy. It has been suggested that the marked
reduction in IGF-I seen during pegvisomant therapy
could remove feedback inhibition of pituitary GH
secretion and induce tumor growth (49). GH levels do
rise initially following pegvisomant treatment but pla-
teau quickly; this is not accompanied by a parallel
increase in overall tumor size in large studies and
during longer-term follow-up (48, 50). However, in
one multicenter study two cases of significant increases
in adenoma size were reported (51). In both cases,
patients had established aggressive tumors, had
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previously undergone failed pituitary surgery and had
large residual tumors still present at entry to the
study. Neither patient had received previous radiother-
apy. One patient, a 26 year-old woman, received inter-
mittent pegvisomant over a 15-month period and then
underwent radiotherapy. In this case tumor size also
increased during a 7-month period spent not receiving
any medical therapy. The other patient was also young
(34 years old) and had a large tumor at diagnosis,
which was still impinging on the optic chiasm 6
months after initial surgery (51). He was only partially
responsive to octreotide therapy and, despite pegviso-
mant therapy up to a maximum dose of 40mg/day,
IGF-I levels remained elevated and eventually began
to rise. At the time of this IGF-I escape, his tumor
began to cause visual symptoms and he was treated
with a combination of octreotide and pegvisomant,
which controlled IGF-I and resolved visual symptoms.
Withdrawal of pegvisomant led to an increase in IGF-
I and a second surgical intervention was undertaken
successfully. Since these early studies, pegvisomant
has been used in the clinical setting in more than
1300 patients and has also been the subject of other
prospective clinical trials in which tumor volume was
assessed by regular MRI scans. A total of 313 patients
have received pegvisomant during the course of com-
pleted prospective trials with a mean treatment dur-
ation of 17 months (Pfizer, data on file). During MRI
follow-up in these clinical trials, increases in tumor
size have been noted in seven further cases. In four of
these cases the tumor size increase consisted of re-
expansion of the adenoma following withdrawal of
octreotide LAR. As noted above, this phenomenon
has previously been reported to occur on cessation of
somatostatin analog therapy (41–43). During pro-
longed pegvisomant treatment of up to 18 months,
no further tumor growth was seen in these patients.
The remaining cases constituted continued progression
of tumors that were noted to be actively growing off
therapy (n ¼ 1) or tumors that were noted to be grow-
ing during somatostatin analog therapy (n ¼ 2). None
of the patients with tumor enlargement while receiving
pegvisomant had undergone previous radiotherapy,
which is in keeping with the high efficacy of radiother-
apy in controlling tumor size. Taking all available data,
this suggests that tumor progression during pegviso-
mant therapy occurs in approximately 2–3% of
patients (5–9/313; depending on the inclusion of
those with re-expansion post octreotide withdrawal)
in the medium term. Further data on pegvisomant in
larger populations of patients treated in the clinical set-
ting and followed with regular MRI will be needed to
assess the effects on tumor progression during long-
term treatment.
Dopamine agonists Dopamine D2 receptor agonists
have been used to treat acromegaly since the 1970s
(52, 53). Their overall efficacy is, however, limited in
comparison with other therapeutic modalities. In a
review of early clinical studies, Jaffe and Barkan (54)
reported that bromocriptine ‘normalized’ serum GH
(levels ,5mg/l) in 20% of patients and IGF-I in only
10% of cases. More recent studies with newer dopamine
agonists, such as cabergoline, have provided better hor-
monal control (55), particularly in tumors that co-
secrete GH and prolactin (56). Tumor shrinkage during
dopamine agonist therapy for acromegaly varies, being
up to 30% of tumors in some studies (54, 57); the most
marked shrinkage was seen in cases of GH/prolactin
co-secretion (56). Secondary resistance to dopamine
agonist therapy in terms of hormonal secretion can
occur in acromegaly (58), although continued tumor
progression has not been reported.
Radiotherapy
Radiotherapy is an effective treatment for acromegaly
and controls both GH/IGF-I hypersecretion and tumor
growth. Adequate hormonal control is achieved very
slowly (59, 60), which necessitates appropriate medical
therapy in the interim period. As hypopituitarism is a
common side effect and as concerns remain over the
risk of second-tumor formation after radiotherapy,
this modality is an adjunctive treatment for acromegaly
that cannot be controlled by surgery or medical therapy
(61). Hormonal control with modern radiotherapeutic
techniques like gamma-knife ‘radiosurgery’ increases
gradually over time but the speed of response and the
effects in terms controlling tumor growth have not
yet been established in sufficiently large patient popu-
lations, although some early results are encouraging
(62). Individual patients with aggressive tumors in
acromegaly can exhibit persistent tumor growth despite
both surgery and radiotherapy (63). However, tumor
expansion after radiotherapy in acromegaly is unusual
and occurs in only 0.3% of cases (59).
Conclusions
Multiple forms of therapy are available to achieve con-
trol of symptoms, hormonal secretion and tumor
growth in acromegaly. Despite the wealth of data gener-
ated by pharmacological and other intervention studies
in acromegaly, our assessment of the literature has
revealed that relatively little attention has been paid
to treatment-resistant acromegaly, particularly in
terms of tumor progression. Tumor recurrence after
apparently complete surgical resection occurs in less
than 10% of cases overall (4, 9, 10), while radiotherapy
fails to control tumor growth in less than 1% of cases
(59) (Table 1). With medical therapy the data are less
clear-cut, as potential confounding effects, such as
pre-selection of treatment-responder subgroups, vari-
ation in disease severity, and any administered pretreat-
ment, make interpretation imprecise. Somatostatin
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analogs were shown to induce a variable degree of
tumor shrinkage in 21 and 52% of patients that
received adjunctive or primary therapy, respectively.
These results come predominantly from studies in
which patients were demonstrated to be somatostatin
analog-sensitive before somatostatin analog therapy
was initiated (37). Tumor progression appears to
occur in up to 2.2% of patients treated with somato-
statin analogs (37, 36), but data on these patients
and their tumor characteristics are very scant. With-
drawal of somatostatin analog therapy can be associ-
ated with re-expansion of pituitary tumors to their
pre-treatment levels (2, 41, 42, 43, 44). Attention
has been focused on pegvisomant in terms of tumor
growth, which occurred in 1.6% of patients treated in
clinical trials, rising to 2.9% if cases of tumor re-expan-
sion on cessation of somatostatin analog therapy are
included. Data describing the natural history of tumor
growth in acromegaly do not exist, so it is impossible
to state whether these rates of failure to control
tumor growth are more or less than those that would
be expected due to the innate behavior of aggressive
tumors. Some factors may be predictive of continued
tumor progression, including young age at diagnosis,
high GH levels, large or extensive tumors, familial
disease and various pathological indices (Table 2).
There exists a clear need to study the causes and
management of treatment-resistant acromegaly, parti-
cularly in terms of tumor progression. Well-designed
MRI studies in patients potentially at risk from an
aggressive tumor would be very useful to verify the
true rates of therapeutic failure across all treatment
modalities.
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